A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of a Single Oral Dose of VV913 Capsules in Chinese Healthy Participants
Latest Information Update: 04 Feb 2026
At a glance
- Drugs VV 913 (Primary)
- Indications Premature ejaculation
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Vigonvita Life Sciences
Most Recent Events
- 04 Feb 2026 New trial record